Abstract 5221: Plasma Levels of Tetrahydrobiopterin and Endothelial Function Were Improved by Fenofibrate Treatment in Patients with Hypertriglyceridemia

Li Y. He,Shan Liu,Jie M. Mao,Xin H. Feng,Jie L. Feng,Guang Wang

DOI: https://doi.org/10.1161/circ.120.suppl_18.s1073

IF: 37.8

2009-01-01

Circulation

Abstract:Background: Endothelial nitric oxide synthase (eNOS) catalytic activity becomes “uncoupled” when tetrahydrobiopterin (BH 4 ) is limiting or absent which causes the endothelial function to be impaird. The objective of our study was to investigate the effects of peroxisome proliferator-activated receptor α (PPAR α ) agonists fenofibrate on plasma levels of nitric oxide (NO) and BH 4 and endothelial function in patients with hypertriglyceridemia. Methods and results: Sixty patients with hypertriglyceridemia were randomly divided into treatment group and the control group. The treatment group (mean follow-up was 145±51 days) was treated with lifestyle changes and fenofibrate 200mg/d; the control group was treated with lifestyle changes only. At the end of the follow-up, plasma NO (99.09±35.51 μ mol/L vs.121.98±53.27 μ mol/L, P < 0.05) and BH 4 (1.48±0.79pmol/mL vs. 2.16±1.50pmol/mL, P < 0.05) levels were elevated and plasma homocysteine (Hcy) levels were elevated by 50.1% ( P < 0.001) compared with the baseline, coronary flow reserve which reflected coronary endothelial function were improved (2.89±0.78 vs. 3.14±0.67, P < 0.05). Fenofibrate could elevate the plasma BH 4 levels (1.39±0.77 pmol/mL vs. 2.31±1.70 pmol/mL, P < 0.01) in patients whose baseline Hcy ≤ 15 μ mol/L; but could not change the plasma BH 4 levels (1.71±0.83 pmol/mL vs. 1.73±0.58 pmol/mL, P > 0.05) in patients whose baseline Hcy > 15 μ mol/L. Furthermore, fenofibrate could elevate plasma BH 4 levels only in patients whose Hcy levels ≤15 μ mol/L at baseline and at the end of follow-up (1.27±0.78 pmol/mL vs. 2.47±2.07 pmol/mL, P < 0.05), and couldn’t change plasma BH 4 levels in patients whose Hcy levels > 15 μ mol/L at baseline and at the end of follow-up(1.68±0.87 pmol/mL vs. 1.76±0.61 pmol/mL, P > 0.05). Conclusion: Fenofibrate can improve endothelial function in patients with hypertriglyceridemia which might relate to the increased expression of NO and BH 4 by fenofibrate. Fenofibrate might inhibit the effects of Hcy in decreasing BH 4 and impairing of the endothelial function, and elevated Hcy might partially inhibit the effects of fenofibrate in increasing BH 4 and improving the vascular endothelial function.